Gilead Sciences Inc gets European Commission's approval for marketing once-daily Viread
Nov 28, 2012 (Menafn - M2 EQUITYBITES via COMTEX) --Biopharmaceutical company Gilead Sciences Inc (nasdaqgs:GILD) reported on Tuesday the receipt of approval from the European Commission for marketing two new indications of once-daily Viread (tenofovir disoproxil fumarate) in all 27 countries of the European Union (EU).
The company said that the first new indication permits the use of Viread in combination with other antiretroviral agents for the treatment of HIV-1 infected pediatric patients aged two to less than 18 years with nucleoside reverse transcriptase inhibitor (NRTI) resistance or toxicities precluding the use of first line pediatric agents.
Concurrently, the second indication allows the use of full-strength 245 mg Viread for the treatment of chronic hepatitis B virus (HBV) infection in adolescent patients aged 12 to less than 18 years with compensated liver disease and evidence of immune active disease.
According to the company, the agency has approved three new reduced-strength Viread tablets in doses of 123 mg, 163 mg and 204 mg for HIV-1 infected children aged six to less than 12 years.
Comments on this story may be sent to firstname.lastname@example.org
(C)1994-2012 M2 COMMUNICATIONS http://www.m2.com